More than 35 million people in the U.S. have chronic kidney disease (CKD), a condition in which the kidneys are damaged and ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

GPs struggle to integrate albuminuria screening for chronic kidney disease due to confusion over prescribing and interpreting ...

Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.